CD3D & CD3E Protein (C-Flag & His, Human)

1.Flow cytometric analysis of anti-CD3 (OKT3 derived) CAR expression. 5e5 of anti-CD3 CAR-293 cells were stained with 100 μL of 1:50 (2 μL stock solution in 100 μL FACS buffer) of APC-conjugated human CD3D & CD3E Heterodimer Protein (Site-Specific APC Conjugation, Flag & His Tag, Cat. No. CT038-H2586H-SA) and negative control protein. Non-transduced 293 cells were used as a control (left) . APC signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of APC-conjugated CD3D & CD3E protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and APC-conjugated human CD3D & CD3E Heterodimer Protein (Site-Specific APC Conjugation, Flag & His Tag, Cat. No. CT038-H2586H-SA) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) . 3.1E5 of mouse Anti-CD3 antibody-conjugated beads (6-8 μm) were stained with a series of concentrations of APC-conjugated human CD3D & CD3E Heterodimer Protein (Site-Specific APC Conjugation, Flag & His Tag, Cat. No. CT038-H2586H-SA) . Binding activity was quantified based on APC fluorescence. The recommended usage is 2 μL per 100 μL staining volume (end-user titration is recommended for optimal performance) .